13 Data Sets

Survival status and ctDNA levels for patients receiving pembrolizumab

A data frame with 94 rows and 15 variables:

id Patient ID
age Age at study entry
sex Patient Sex
cohort Study Cohort: A = Squamous cell carcinoma of soft pallate, B = Triple negative breast cancer, C = Ovarian, high grade serous, D = Melanoma, E = Other Solid Tumor
l_size Target lesion size at baseline
pdl1 PD L1 percent
tmb log of TMB
baseline_ctdna Baseline ctDNA
change_ctdna_group Did ctDNA increase or decrease from baseline to cycle 3
orr Objective Response
cbr Clinical Beneficial Response
os_status Overall survival status, 0 = alive, 1 = deceased
os_time Overall survival time in months
pfs_status Progression free survival status, 0 = progression free, 1 = progressed
pfs_time Progression free survival time in months

Longitudinal changes in tumour size since baseline for patients by changes in ctDNA status (clearance, decrease or increase) since baseline.

A data frame with 270 rows and 5 variables:

id Patient ID
cohort Study Cohort: A = Squamous cell carcinoma of soft pallate, B = Triple negative breast cancer, C = Ovarian, high grade serous, D = Melanoma, E = Other Solid Tumor
ctdna_status Change in ctDNA since baseline
time Number of weeks on treatment
size_change Percentage change in tumour measurement